Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCT
This episode covers treatments for relapsed/refractory CLL including acalabrutinib, venetoclax, and obinutuzumab. It also discusses alternative donor transplantation for severe aplastic anemia and clonal relapse dynamics in AML following allogeneic hematopoietic cell…